Skip to main content
SpringerLink
Log in

The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Most of the current clinical data on the role of 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (18F-FDG-PET) in musculoskeletal tumors come from patients studied with PET and less frequently with hardware fusion PET/computed tomography (CT). And the number of cases in each report is too small to clarify the exact clinical efficacy of PET or PET/CT. This prompted us to analyze our experience with 18F-FDG-PET/CT in a relatively large group of patients with musculoskeletal tumors.

Methods

18F-FDG-PET/CT was performed on 91 patients from May 2004 to June 2007. The final diagnosis was obtained from surgical biopsy in 83 patients (91%) and clinical follow-up in 8 (9%). We analyzed the characteristics and amount of 18F-FDG uptake in soft tissue and bone tumors, and investigated the ability of 18F-FDG-PET/CT to differentiate malignant from benign tumors. The cutoff maximum standardized uptake value (SUVmax) was calculated using the receiver-operation characteristic curve method. Sensitivity, specificity, and diagnostic accuracy were calculated with cutoff SUVmax and the final diagnosis. Unpaired t test was used for the statistical analysis.

Results

Final diagnosis revealed 19 benign soft tissue tumors (mean SUVmax 4.7), 27 benign bone tumors (5.1), 25 malignant soft tissue tumors (8.8), and 20 malignant bone tumors (10.8). There was a significant difference in SUVmax between benign and malignant musculoskeletal tumors in total (P < 0.002), soft tissue tumors (P < 0.05), and bone tumors (P < 0.02). Sensitivity, specificity, and diagnostic accuracy were 80%, 65.2%, and 73% in total with cutoff SUVmax 3.8, 80%, 68.4%, and 75% in the soft tissue tumors with cutoff SUVmax 3.8, and 80%, 63%, and 70% in the bone tumors with cutoff SUVmax 3.7.

Conclusions

18F-FDG-PET/CT reliably differentiated malignant soft tissue and bone tumors from benign ones, although there were many false-positive and falsenegative lesions. Further studies with all kinds of musculoskeletal tumors in large numbers are needed to improve the diagnostic accuracy of 18F-FDG-PET/CT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683–693.

    Article  PubMed  CAS  Google Scholar 

  2. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380–386.

    Article  PubMed  CAS  Google Scholar 

  3. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, et al. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001;28:704–710.

    Article  PubMed  CAS  Google Scholar 

  4. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003;32:133–138.

    PubMed  CAS  Google Scholar 

  5. Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, et al. FDG-PET for evaluating musculoskeletal tumors. J Orthop Sci 2003;8:435–441.

    Article  PubMed  Google Scholar 

  6. Feldman F, Heertum RV, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003;32:201–208.

    PubMed  Google Scholar 

  7. Taira AV, Herfkens RJ, Gambhir SS, Quon A. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology 2007;243:204–211.

    Article  PubMed  Google Scholar 

  8. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106:29–34.

    Article  PubMed  Google Scholar 

  9. Iagaru A, Quon A, McDougall IR, Gambhir SS. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med 2006;31:754–760.

    Article  PubMed  Google Scholar 

  10. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005;184:1293–1304.

    PubMed  Google Scholar 

  11. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspect and clinical applications. Semin Nucl Med 2003;33:205–218.

    Article  PubMed  Google Scholar 

  12. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356–1367.

    PubMed  Google Scholar 

  13. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG pet as part of the same PET/CT examination. Radiology 2005;237:627–634.

    Article  PubMed  Google Scholar 

  14. Even-Sapir E, Metser U, Flusser G, Zuriel LM, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272–278.

    PubMed  Google Scholar 

  15. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–1209.

    PubMed  Google Scholar 

  16. Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-d-glucose. Radiology 1996;200:243–247.

    PubMed  CAS  Google Scholar 

  17. Lucas JD, O’Doherty MJ, Wong JC, Bingham JB, McKee PH, Fletcher CD, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of softtissue sarcomas. J Bone Joint Surg Br 1998;80:441–447.

    Article  PubMed  CAS  Google Scholar 

  18. Mester U, Even-Sapir E. Increased 18F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007;37:206–222.

    Article  Google Scholar 

  19. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510–518.

    PubMed  Google Scholar 

  20. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219:774–777.

    PubMed  CAS  Google Scholar 

  21. Hamada K, Tomita Y, Ueda T, Enomoto K, Kakunaga S, Myoui A, et al. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft tissue tumors. Ann Nucl Med 2006;20:671–675.

    Article  PubMed  CAS  Google Scholar 

  22. Suzuki R, Watanabe H, Yanagawa T, Sato J, Shinozaki T, Suzuki H, et al. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value to differentiate benign tumors from liposarcoma. Ann Nucl Med 2005;19:661–670.

    PubMed  Google Scholar 

  23. Aoki J, Watanabe H, Shinozaki T, Tokunaga M, Inoue T, Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999;23:603–608.

    Article  PubMed  CAS  Google Scholar 

  24. Brenner W Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004;31:189–195.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, College of Medicine, Yeungnam University, 317-1 Daemyung-Dong, Nam-Gu, Daegu, 705-717, South Korea

    Duk-Seop Shin, Oog-Jin Shon & Dong-Sung Han

  2. Department of Surgical Pathology, College of Medicine, Yeungnam University, Daegu, South Korea

    Joon-Hyuk Choi

  3. Department of Nuclear Medicine, College of Medicine, Yeungnam University, Daegu, South Korea

    Kyung-Ah Chun & Ihn-Ho Cho

Authors
  1. Duk-Seop Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oog-Jin Shon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Sung Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joon-Hyuk Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyung-Ah Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ihn-Ho Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Duk-Seop Shin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shin, DS., Shon, OJ., Han, DS. et al. The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med 22, 603–609 (2008). https://doi.org/10.1007/s12149-008-0151-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-008-0151-2

Keywords

Search

Navigation